A further kinase assay confirms that these inhibitors can generally target their noncognate kinases HER3 and BRaf in cervical cancer with a high or moderate activity; the activity profile are comparable with or even better than that of cognate kinases inhibitors, with IC<sub>50</sub> values ranging between 4.8 and 340.6 nM for HER3 and between 37.2 and 638.2 nM for BRaf.
Increased expression level of Erb-b2 receptor tyrosine kinase 3 (ERBB3) has previously been demonstrated to be associated with the occurrence of cervical cancer; however, the functionality of ERBB3 in the development of cervical cancer remains incompletely understood.
The objectives of this study were to observe the changes in expression of ErbB-3 binding protein (Ebp1) in cervical cancer and to investigate their clinic significance.
Three proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).